The Role of High Dose Interleukin-2 in the Era of Targeted Therapy

被引:3
|
作者
Gills, Jessie
Parker, William P.
Pate, Scott
Niu, Sida
Van Veldhuizen, Peter
Mirza, Moben
Holzbeierlein, Jeffery M.
Lee, Eugene K.
机构
来源
JOURNAL OF UROLOGY | 2017年 / 198卷 / 03期
关键词
kidney; carcinoma; renal cell; neoplasm metastasis; interleukin-2; molecular targeted therapy; RENAL-CELL CARCINOMA; RECOMBINANT HUMAN INTERLEUKIN-2; PHASE-II; SURVIVAL; SORAFENIB; SUNITINIB; CANCER; RESPONSES; EFFICACY; CRITERIA;
D O I
10.1016/j.juro.2017.03.076
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We assessed survival outcomes following high dose interleukin-2 in a contemporary cohort of patients during the era of targeted agents. Materials and Methods: We retrospectively reviewed the records of patients with metastatic renal cell carcinoma treated with high dose interleukin-2 between July 2007 and September 2014. Clinicopathological data were abstracted and patient response to therapy was based on RECIST (Response Evaluation Criteria In Solid Tumors), version 1.1 criteria. The Kaplan-Meier method was used to estimate progression-free and overall survival in the entire cohort, the response to high dose interleukin-2 in regard to previous targeted agent therapy and the response to the targeted agent in relation to the response to high dose interleukin-2. Results: We identified 92 patients, of whom 87 had documentation of a response to high dose interleukin-2. Median overall survival was 34.4 months from the initiation of high dose interleukin-2 therapy in the entire cohort. Patients who received targeted therapy before high dose interleukin-2 had overall survival (median 34.4 and 30.0 months, p = 0.88) and progression-free survival (median 1.5 and 1.7 months, p = 0.8) similar to those in patients who received no prior therapy, respectively. Additionally, patients with a complete or partial response to high dose interleukin-2 had similar outcomes for subsequent targeted agents compared to patients whose best response was stable or progressive disease (median overall survival 30.1 vs 25.4 months, p = 0.4). Conclusions: Our data demonstrate that patient responses to high dose interleukin-2 and to targeted agents before and after receiving high dose interleukin-2 are independent. As such, carefully selected patients should be offered high dose interleukin-2 for the possibility of a complete and durable response without the fear of limiting the treatment benefit of targeted agents.
引用
收藏
页码:538 / 545
页数:8
相关论文
共 50 条
  • [21] High Dose Inhalation Interleukin-2 Therapy for Lung Metastases in Patients with Malignant Melanoma
    Weihsengruber, F.
    Bartsch, K.
    Rappersberger, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 (09): : 837 - 837
  • [22] HIGH-DOSE INTERLEUKIN-2 IN THE THERAPY OF METASTATIC RENAL-CELL CARCINOMA
    PARKINSON, DR
    SZNOL, M
    SEMINARS IN ONCOLOGY, 1995, 22 (01) : 61 - 66
  • [23] High-dose interleukin-2 therapy related adverse events and implications on imaging
    Shah, Neal R.
    Declouette, Brandon
    Ansari-Gilani, Kianoush
    Alhomoud, Mohammad S.
    Hoimes, Christopher
    Ramaiya, Nikhil H.
    Guler, Ezgi
    DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2021, 27 (05) : 684 - 689
  • [24] High Dose Inhalation Interleukin-2 Therapy for Lung Metastases in Patients with Malignant Melanoma
    Bartsch, K.
    Weihsengruber, F.
    Rappersberger, K.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 : S29 - S29
  • [25] Managing toxicities of high-dose interleukin-2
    Schwartz, RN
    Stover, L
    Dutcher, J
    ONCOLOGY-NEW YORK, 2002, 16 (11): : 11 - 20
  • [26] COMPLEMENT ACTIVATION AND HIGH-DOSE OF INTERLEUKIN-2
    THIJS, LG
    HACK, CE
    VANSCHIJNDEL, RJMS
    NUIJENS, JH
    WOLBINK, GJ
    EERENBERGBELMER, AJM
    VANDERVALL, H
    WAGSTAFF, J
    LANCET, 1989, 2 (8659): : 395 - 395
  • [27] Focal Takotsubo Cardiomyopathy With High-Dose Interleukin-2 Therapy for Malignant Melanoma
    Damodaran, Senthil
    Mrozek, Ewa
    Liebner, David
    Kendra, Kari
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (12): : 1666 - 1670
  • [28] High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma
    Enk, AH
    Nashan, D
    Rübben, A
    Knop, J
    CANCER, 2000, 88 (09) : 2042 - 2046
  • [29] THE ROLE OF RECOMBINANT INTERLEUKIN-2 IN THERAPY FOR HEMATOLOGIC MALIGNANCIES
    DUTCHER, JP
    WIERNIK, PH
    SEMINARS IN ONCOLOGY, 1993, 20 (06) : 33 - 40
  • [30] INTERLEUKIN-2 RECEPTOR-TARGETED THERAPY IN ISLET TRANSPLANTATION RESEARCH
    HAHN, HJ
    KUTTLER, B
    VOLK, HD
    LUCKE, S
    DIAMANTSTEIN, T
    HORMONE AND METABOLIC RESEARCH, 1990, 25 : 177 - 180